The critical function of IRF1 in the immune systems of various cancers has been explored (Kirchhoff et al., 1993; Kim et al., 2002), the clinical application and biological function of IRF1 in NSCLC patients who receiving chemoimmunotherapy remains unknown. Here, IRF1 is linked to non-small cell lung carcinoma.